Policy watch. Analysis of Medicare drug plans reveals variance in value and in formularies' coverage.
- Published in:
- 2006
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2006 AND VI 41 AND IP 5
Results: 34
1
2
No reduction in primary end point with pexelizumab.
- Published in:
- 2006
- Publication type:
- Journal Article
3
Fondaparinux reduces event rate in ST-segment elevation MI, except in primary PCI.
- Published in:
- 2006
- Publication type:
- Journal Article
4
Coronary atherosclerosis regression possible with intensive statin therapy.
- Published in:
- 2006
- Publication type:
- Journal Article
5
Dual antiplatelet therapy fails to reduce CV event risk in high-risk patients.
- Published in:
- 2006
- Publication type:
- Journal Article
6
Drug watch. Antibiotics.
- Published in:
- 2006
- Publication type:
- Journal Article
7
55th Annual Scientific Session focuses on continuing research, emerging clinical trial data.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
8
Bivalirudin alone leads to net clinical benefit in ACS.
- Published in:
- 2006
- Publication type:
- Journal Article
9
Focus on... Full-length human recombinant parathyroid hormone for the treatment of osteoporosis.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
10
Antibiotics.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 256
- Publication type:
- Article
11
Selected literature.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 256
- Publication type:
- Article
12
Analysis of Medicare drug plans reveals variance in value and in formularies' coverage.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 255
- Publication type:
- Article
13
No reduction in primary end point with pexelizumab.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 246
- Publication type:
- Article
14
FDA's 'Critical Path' initiative could lay groundwork for expedited drug development, quality improvement.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 255
- By:
- Publication type:
- Article
15
CMS addresses redundancies in Medicare drug plan as it composes formulary and coverage policies for 2007.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 254
- By:
- Publication type:
- Article
16
Clostridium difficile infections on rise in United States at short-stay facilities.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 250
- Publication type:
- Article
17
Enoxaparin demonstrates net clinical benefit in ST-segment elevation MI.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 236
- Publication type:
- Article
18
Statin therapy within 24 hours of hospital admission associated with lower risk of CHF and in-hospital death.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 250
- Publication type:
- Article
19
Carvedilol at discharge associated with improved early survival in heart failure.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 246
- Publication type:
- Article
20
Postoperative AF blunted by statin pretreatment.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 244
- Publication type:
- Article
21
Coronary atherosclerosis regression possible with intensive statin therapy.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 242
- Publication type:
- Article
22
Fondaparinux reduces event rate in ST-segment elevation MI, except in primary PCI.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 241
- Publication type:
- Article
23
Dual antiplatelet therapy fails to reduce CV event risk in high-risk patients.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 237
- Publication type:
- Article
24
Full-length human recombinant parathyroid hormone for the treatment of osteoporosis.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 214
- By:
- Publication type:
- Article
25
Lymphoma risk in RA associated with inflammatory burden, not treatment.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 231
- Publication type:
- Article
26
Abciximab reduces adverse event risk in ACS patients pretreated with clopidogrel.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 236
- Publication type:
- Article
27
Bivalirudin alone leads to net clinical benefit in ACS.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 232
- Publication type:
- Article
28
55th Annual Scientific Session focuses on continuing research, emerging clinical trial data.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 232
- By:
- Publication type:
- Article
29
Safety.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 231
- Publication type:
- Article
30
FDA actions in brief.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 213
- Publication type:
- Article
31
New formulations.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 213
- Publication type:
- Article
32
First-time generic approvals.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 213
- Publication type:
- Article
33
Pipeline preview.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 213
- Publication type:
- Article
34
Focus on….
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 210
- Publication type:
- Article